Skip to main content
Jiangxi Fushine Pharmaceutical Co.,Ltd. logo

Jiangxi Fushine Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 300497 ISIN · CNE1000024Z7 LEI · 836800CKYVE9KWZZTV84 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,777 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300497

About Jiangxi Fushine Pharmaceutical Co.,Ltd.

https://www.fushine.cn

Jiangxi Fushine Pharmaceutical Co.,Ltd. specializes in the research, development, manufacture, and global distribution of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company is a prominent producer of beta-lactamase inhibitors, including Tazobactam and Sulbactam, which are essential components in combination antibiotic therapies. Additionally, it maintains a significant market position in the production of carbapenem intermediates, such as those for Meropenem and Imipenem. Fushine Pharmaceutical operates advanced manufacturing facilities that adhere to international Good Manufacturing Practice (GMP) standards, ensuring high-quality outputs for a diverse international clientele. Its core competencies include complex chemical synthesis and large-scale industrial production, supporting the global supply chain for anti-infective and antiviral medications.

Recent filings

Filing Released Lang Actions
2025年年度股东会会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is an announcement of the resolutions and detailed vote results from the company’s 2025 Annual General Meeting. It reports attendance, each proposal, voting tallies (for/against/abstain), and resolution outcomes. This matches the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-21 Chinese
北京市中伦律师事务所关于江西富祥药业股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a legal opinion letter from Zhong Lun law firm regarding the convening, procedures, attendee qualifications, and detailed vote tallies at the 2025 annual shareholders’ meeting of Jiangxi Fuxiang Pharmaceutical Co., Ltd. It is not a simple notice of an upcoming meeting (DIV/PSI), nor a general annual report (10-K) or management discussion (MDA), but it provides the official voting results for each resolution at the AGM. This matches the Definition of Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-21 Chinese
关于控股股东部分股份解除质押的公告
Regulatory Filings Classification · 82% confidence The document is a formal company announcement (in Chinese) regarding the release of a pledge on shares held by the controlling shareholder. It does not contain financial statements, dividend notices, merger details, or the report itself; nor does it involve share issuances, repurchases, threshold-crossing ownership changes, or a director’s purchase/sale of shares. This type of corporate disclosure is a general regulatory filing announcing a collateral change for a major shareholder’s shares. It best fits the fallback category Regulatory Filings (RNS).
2026-05-20 Chinese
关于特定股东股份减持计划预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a specific shareholder's plan to reduce their shareholding in the company. It details the shareholder's name, shareholding percentage, planned reduction amount, methods, timing, and related commitments. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory disclosure about a planned shareholding reduction by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on this notification, not a report or announcement of a report publication.
2026-05-19 Chinese
关于公司控股股东部分股份质押的公告
Regulatory Filings Classification · 75% confidence The document is a formal corporate announcement by Jiangxi Fuxiang Pharmaceutical Co., Ltd. disclosing the pledge of shares by its controlling shareholder. It does not contain financial statements or represent a full report (e.g., Annual/Interim Report), nor is it an earnings release, proxy solicitation, dividend notice, M&A document, share issue, or repurchase. It is a mandatory regulatory disclosure of share pledge details by a major shareholder. This falls under the general “Regulatory Filings” category (RNS) as a fallback for miscellaneous required disclosures.
2026-05-19 Chinese
关于取得日内瓦国际发明展金奖的公告（1）
Regulatory Filings Classification · 76% confidence The document is a corporate announcement by Jiangxi Fuxiang Pharmaceutical Co., Ltd. declaring that it received a gold award at the Geneva International Exhibition of Inventions. It contains no financial statements, management changes, dividend details, or other specific categories. It is a general regulatory announcement about a company event/award. No other more specific filing category applies, so it falls under the fallback category “Regulatory Filings (RNS).”
2026-05-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.